Skip to main content
Genine Winslow

Genine Winslow, MS

CEO, Editpep
United States
Co- Founder and CEO of Editpep, producing CRISPR based therapeutics by leveraging a delivery platform developed at UC Berkeley by Dr. Ross Wilson, a Jennifer Doudna lab alumnus. Entrepreneur and company builder focused on genetic medicines to treat unmet need. Expertise includes gene therapy and exosome based CMC, Immunology, genetic medicine drug development and regulatory guidelines. Heald multiple leadership roles in cross-functional teams to develop early stage genetic medicine products. I am a creative thinker with independent, proactive problem solving abilities and enthusiasm for challenges with an unfailingly positive attitude. MSc in Immunology from the department of Cell and Molecular Biology at the University of California at Berkeley focusing on T cell activation. Over 20 years of experience in successful rare disease drug discovery and development in genetic medicines contributing to regulatory filings and resulting in patents and publications, and drugs on the market. Graduate research at UC Berkeley in T Cell activation in Lab of James P Allison. Prior drug developement experience from Bluebird Bio, BioMarin and Audentes Therapeutics with Adeno Associated Virus and Lentivirus based therapeutics.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.